Acurx Pharmaceuticals Faces Delisting Notice
Ticker: ACXP · Form: 8-K · Filed: Mar 28, 2025 · CIK: 1736243
Sentiment: bearish
Topics: delisting, listing-standards, compliance
Related Tickers: ACRX
TL;DR
ACRX got a delisting warning, might get moved to a different exchange.
AI Summary
Acurx Pharmaceuticals, Inc. received a notice on March 25, 2025, indicating a failure to meet a continued listing rule or standard, potentially leading to a transfer of listing. The company is incorporated in Delaware and its principal executive offices are located at 259 Liberty Avenue, Staten Island, NY.
Why It Matters
This notice suggests potential financial distress or non-compliance with exchange rules, which could significantly impact the company's stock value and trading accessibility.
Risk Assessment
Risk Level: high — A notice of delisting or failure to meet listing standards is a severe warning that can lead to significant stock price declines and trading disruptions.
Key Players & Entities
- Acurx Pharmaceuticals, Inc. (company) — Registrant
- March 25, 2025 (date) — Date of earliest event reported
- 259 Liberty Avenue, Staten Island, NY 10305 (address) — Principal executive offices
- 001-40536 (company_id) — Commission File Number
FAQ
What specific listing rule or standard did Acurx Pharmaceuticals fail to meet?
The filing states that Acurx Pharmaceuticals, Inc. received a notice of "Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing" but does not specify the exact rule or standard that was violated.
What is the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is March 25, 2025.
What is the company's principal executive office address?
The company's principal executive offices are located at 259 Liberty Avenue, Staten Island, NY 10305.
What is Acurx Pharmaceuticals' Commission File Number?
Acurx Pharmaceuticals' Commission File Number is 001-40536.
What is the potential consequence of failing to meet listing standards mentioned in the filing?
The filing indicates a potential "Transfer of Listing" as a consequence of failing to satisfy a continued listing rule or standard.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 28, 2025 regarding Acurx Pharmaceuticals, Inc. (ACXP).